Valuation: Allied Corp.

Market Cap 1.3M 1.13M 1.05M 966K 1.82M 124M 1.85M 12.35M 4.85M 62.19M 4.9M 4.79M 206M P/E 2023
-2.13x
P/E 2024 -2.52x
Enterprise Value 7.55M 6.53M 6.1M 5.6M 10.52M 719M 10.69M 71.56M 28.09M 360M 28.36M 27.74M 1.19B EV / Sales 2023
394,366,816x
EV / Sales 2024 171,944,593x
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
1 week+1,109,900.00%
Current month+1,109,900.00%
1 month+1,109,900.00%
3 months+1,109,900.00%
6 months+1,109,900.00%
Current year+2,120.00%
1 week 0
Extreme 1.0E-6
0.01
1 month 0
Extreme 1.0E-6
0.01
Current year 0
Extreme 1.0E-6
0.01
1 year 0
Extreme 1.0E-6
0.01
3 years 0
Extreme 1.0E-6
0.26
5 years 0
Extreme 1.0E-6
2.15
10 years 0
Extreme 1.0E-6
4.5
Manager TitleAgeSince
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer 71 -
Corporate Officer/Principal - 2020-05-01
Director TitleAgeSince
Director/Board Member - 2020-05-01
Director/Board Member - -
Director/Board Member - 2024-10-20
Date Insider Type Main position Quantity % Market Cap.
4/25/23 Buy

Director

80,000 0.0824%
9/22/20 Buy

Chief Executive Officer

10,000 0.0118%
9/22/20 Other

Chief Executive Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+1,109,900.00%-.--%-95.55% 117
+0.15%+4.35%+79.11%-8.16% 2.46B
-2.78%+1.16%+61.14%+118.48% 1.68B
+1.78%+8.33%-41.15%+172.38% 506M
-3.85%-10.71%0.00%0.00% 54.81M
Average -0.94%+0.63%+19.82%+37.43% 940.77M
Weighted average by Cap. -0.77%+3.46%+58.83%+56.66%

Financials

2023 2024
Net sales 0.07 0.06 0.06 0.05 0.1 6.86 0.1 0.68 0.27 3.44 0.27 0.26 11.37 0.1 0.08 0.08 0.07 0.13 9.15 0.14 0.91 0.36 4.59 0.36 0.35 15.17
Net income -10.68M -9.23M -8.62M -7.91M -14.88M -1.02B -15.12M -101M -39.71M -509M -40.09M -39.21M -1.68B -3.98M -3.44M -3.21M -2.95M -5.54M -378M -5.63M -37.68M -14.79M -190M -14.93M -14.6M -627M
Net Debt 5.65M 4.89M 4.57M 4.19M 7.88M 538M 8M 53.56M 21.02M 270M 21.22M 20.76M 891M 6.25M 5.4M 5.05M 4.63M 8.71M 595M 8.85M 59.21M 23.24M 298M 23.46M 22.95M 985M
Logo Allied Corp.
Allied Corp. is an international medical cannabis production company. The Company is engaged in researching, creating, and producing targeted cannabinoid health solutions. It focuses on the development of Colombian produced medicinal cannabis for patients with conditions potentially suitable for treatment. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder (PTSD), Parkinson’s disease, Tourette’s syndrome, irritable bowel syndrome (IBS) and spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI). Its core hemp-derived cannabidiol (CBD) brands are Tactical Relief Brand, Equilibrium Bio and MaXXa. The Tactical Relief brand's flagship product is a hemp-derived CBD tincture for sale in the United States. The Equilibrium Bio brand is primarily focused on hydration and recovery areas. The MaXXa brand develops natural CBD-infused cosmetics and beauty products.
Employees
-
Date Price Change Volume
26-08-06 US$0.000001 -.--% 200
  1. Stock Market
  2. Stocks
  3. ALID Stock